Literature DB >> 15358591

The blood brain barrier in HIV infection.

Joseph R Berger1, Malcolm Avison.   

Abstract

The blood brain barrier (BBB) serves as a protective mechanism for the brain. It prevents entry of pernicious substances, whether chemical or cellular, from free access to the CNS. In essence, it is a defense mechanism preserving the internal milieu of the brain. The BBB may be disrupted by a number of pathological processes. CNS infection is a well recognized cause of BBB disruption. Among the CNS infections demonstrated to affect the BBB is human immunodeficiency virus (HIV). HIV infects the brain shortly after its acquisition. Studies of cerebrospinal fluid (CSF) as well as dynamic studies of contrast enhanced magnetic resonance imaging have confirmed abnormalities of the BBB in HIV-infected persons. Pathological studies of the CNS have confirmed the in vivo studies, and in vitro studies have identified a range of pathogenic mechanisms of HIV-associated BBB compromise. This disruption of the BBB may not only contribute to accelerating brain infection by HIV, but may also alter CNS function. Additionally, BBB disruption has implications with respect to antiretroviral therapy. This review will address these issues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358591     DOI: 10.2741/1427

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  27 in total

1.  Toll-Like Receptor-3 Mediates HIV-1-Induced Interleukin-6 Expression in the Human Brain Endothelium via TAK1 and JNK Pathways: Implications for Viral Neuropathogenesis.

Authors:  Biju Bhargavan; Georgette D Kanmogne
Journal:  Mol Neurobiol       Date:  2017-11-11       Impact factor: 5.590

2.  Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users.

Authors:  S D Newsome; E Johnson; C Pardo; J C McArthur; A Nath
Journal:  Neurology       Date:  2011-03-01       Impact factor: 9.910

Review 3.  T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disorders.

Authors:  Muhammad Mukhtar; Edward Acheampong; Zahida Parveen; Roger J Pomerantz
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 4.  Current understanding of HIV-associated neurocognitive disorders pathogenesis.

Authors:  Patrick Gannon; Muhammad Z Khan; Dennis L Kolson
Journal:  Curr Opin Neurol       Date:  2011-06       Impact factor: 5.710

5.  Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Gary Siuzdak; Howard S Fox
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

6.  Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Aleksandr Obikhod; David Delinsky; Janarthanan Narayanasamy; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

7.  Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.

Authors:  Huanyu Dou; Cassi B Grotepas; JoEllyn M McMillan; Christopher J Destache; Mahesh Chaubal; Jane Werling; James Kipp; Barrett Rabinow; Howard E Gendelman
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

Review 8.  Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  Neuropsychol Rev       Date:  2009-05-09       Impact factor: 7.444

9.  Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques.

Authors:  William R Wikoff; Gurudutt Pendyala; Gary Siuzdak; Howard S Fox
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

10.  Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain.

Authors:  Penghua Wang; Jianfeng Dai; Fengwei Bai; Kok-Fai Kong; Susan J Wong; Ruth R Montgomery; Joseph A Madri; Erol Fikrig
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.